Board of Directors

Peter Allen Non-Executive Chairman

Peter has a wealth of experience and has held key senior positions, including Chairman, CEO and CFO in a number of companies in the healthcare industry, and played a significant role in their growth.

Peter spent 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO, six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and three years as Chairman of Proximagen Neurosciences plc (2009-2012).


Peter is currently Chairman of None Advanced Medical Solutions Plc, Future Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Macrotarg Ltd.

Shaun Chilton Chief Executive Officer

Shaun joined Clinigen as COO in January 2012 before becoming Deputy CEO in July 2015 and CEO in November 2016. Shaun has responsibility for the Group achieving its key performance indicators and plays a central role in setting and executing the Group strategy.

Shaun has over 25 years’ international industry experience working in both global pharmaceutical companies and global healthcare service
businesses. He has held a wide range of senior strategic, commercial and operational roles and has a long-term track record of growing international businesses and developing effective management teams. Prior to joining Clinigen, Shaun was the President within KnowledgePoint360 Group, a global pharmaceutical information and services operation.

Martin Abell Chief Financial Officer

Martin joined Clinigen in August 2015 and has over 19 years’ experience working for international, listed companies.

Before Clinigen, Martin worked for Hays plc, Europe’s largest professional recruitment business. He began there as Head of Investor Relations and M&A before becoming Finance Director for the Continental Europe and Rest of World division, which operated across 21 countries with revenues of over £1bn. Prior to that, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post), including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.

Peter George Non-Executive Director

Peter joined Clinigen as CEO when it formed and has been at the forefront of the strategic decisions and resulting growth Clinigen has achieved.

Peter has an extensive range of experience, starting his career in the UK’s National Health Service before utilising and strengthening his experience in the pharmaceutical industry where he has held a number of senior international roles, including Executive
VP for Wolters Kluwer Health, with responsibility for European and Asia Pacific regions, CEO at Penn Pharma Limited, where he led a £67m
management buy-out in 2007, and Chief Operating Officer for Unilabs Clinical Trials International Limited.

Peter was CEO of the Year in the 2014 European Mediscience Awards. Peter retired as CEO in November 2016 and remained on the Board
as a Non-Executive Director.


Peter is currently Chairman of None Advanced Medical Solutions Plc, Future Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Macrotarg Ltd.

John Hartup Non-Executive Director

John has over 30 years’ experience as a corporate lawyer, dealing with corporate finance and commercial contract issues across a number of industries. He was formerly Managing Partner at Ricksons LLP and subsequently became a Partner at DWF LLP.


John is currently a Director of Wichtig International Ltd.

Ian Nicholson Non-Executive Director

Ian has considerable experience as both an Executive Director and as a Non-Executive Director. Ian is CEO of F2G Limited.


Ian currently holds positions as Non-Executive Director of Consort Medical plc and Bioventix plc, where he is the Non-Executive Chairman. Ian is also Chairman of the Investment Committee at Cancer Research UK Pioneer Fund, Director of Casewell Consulting Ltd, F2G Ltd, and Wells Stores Ltd, and an Operating Partner at Advent Life Sciences LLP.

John Bacon Non-Executive Director

Previously Chairman of Link Healthcare, John Bacon founded the organisation in the 1990s, thereby pioneering the supply of specialist pharmaceuticals in the Australasian markets. He has qualifications in both science and business and prior to forming Link Healthcare, held senior positions in both fields across the Asia Pacific region.


John is currently a Director of Anggatha Pty Ltd, Budburst Capital Pty Ltd, JK & LJ Superannuation Management Pty Ltd, Ingenia Pty Ltd and Ingenia Developments Pty Ltd.